Regulation of intracellular calcium release and PP1α in a mechanism for 4-hydroxytamoxifen-induced cytotoxicity

Molecular and Cellular Biochemistry

Volumn 305, Issue 1-2, 2007, Pages 45-54

  Bollig, Aliccia ^a   Xu, Liping ^b   Thakur, Archana ^a   Wu, Jiusheng ^a   Kuo, Tuan H ^b   Liao, Joshua D ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

4 Hydroxytamoxifen; Bcl2; Calcium; Endoplasmicreticulum; PP1 alpha; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; ADENOSINE TRIPHOSPHATE; CALCIUM; ESTROGEN RECEPTOR ALPHA; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE ALPHA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; CALCIUM TRANSPORT; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; ENDOPLASMIC RETICULUM; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN FUNCTION; UPREGULATION;

BREAST NEOPLASMS; CALCIUM; CYTOTOXINS; ENDOPLASMIC RETICULUM; HUMANS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; ION TRANSPORT; PROTEIN PHOSPHATASE 1; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 34948884041     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-007-9526-2     Document Type: Article

References (49)

1. Osborne CK, Zhao H, Fuqua SA (2000) Selective estrogen receptor modulators: Structure, function, and clinical use. J Clin Oncol 18(17):3172-3186
2. Watts CK, Sweeney KJ, Warlters A, Musgrove EA, Sutherland RL (1994) Antiestrogen regulation of cell cycle progression and cyclin D1 gene expression in MCF-7 human breast cancer cells. Breast Cancer Res Treat 31(1):95-105
3. Tchou J, Hou N, Rademaker A, Jordan VC, Morrow M (2004) Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer 100(9):1800-1806
4. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295(23):2727-2741
5. Lonning PE, Hall K, Aakvaag A, Lien EA (1992) Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res 52(17):4719-4723
6. Lee JE, Chung KW, Han W, Kim SW, Shin HJ, Bae JY, Noh DY (2004) Effect of estrogen, tamoxifen and epidermal growth factor on the transcriptional regulation of vascular endothelial growth factor in breast cancer cells. Anticancer Res 24(6):3961-3964
7. Helguero LA, Faulds MH, Gustafsson JA, Haldosen LA (2005) Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 24(44):6605-6616
8. Borgna JL, Rochefort H (1980) High-affinity binding to the estrogen receptor of [3H]4-hydroxytamoxifen, an active antiestrogen metabolite. Mol Cell Endo 20:71-85
9. Somai S, Chaouat M, Jacob D, Perrot JY, Rostene W, Forgez P, Gompel A (2003) Antiestrogens are pro-apoptotic in normal human breast epithelial cells. Int J Cancer 105(5):607-612
10. Jordan VC, Lewis JS, Osipo C, Cheng D (2005) The apoptotic action of estrogen following exhaustive antihormonal therapy: A new clinical treatment strategy. Breast 14(6):624-630
11. Furr BJ, Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25(2):127-205
12. Decensi A, Robertson C, Viale G et al (2003) A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. JNCI 95:779-790
13. Peyrade F, Frenay M, Etienne MC, Ruch F, Guillemare C, Francois E, Namer M, Ferrero JM, Milano G (1996) Age-related difference in tamoxifen disposition. Clin Pharmacol Ther 59(4):401-410
14. MacCallum J, Cummings J, Dixon JM, Miller WR (2000) Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours. Br J Cancer 82(10):1629-1635
15. Kallio A, Zheng A, Dahllund J, Heiskanen KM, Harkonen P (2005) Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. Apoptosis 10(6):1395-1410
16. Chiarenza A, Lazarovici P, Lempereur L, Cantarella G, Bianchi A, Bernardini R (2001) Tamoxifen inhibits nerve growth factor-induced proliferation of the human breast cancerous cell line MCF-7. Cancer Res 61(7):3002-3008
17. Jain PT, Trump BF (1997) Tamoxifen induces deregulation of [Ca2+] in human breast cancer cells. Anticancer Res 17(2A):1167-1174
18. Iwao K, Miyoshi Y, Egawa C, Ikeda N, Noguchi S (2000) Quantitative analysis of estrogen receptor-beta mRNA and its variants in human breast cancers. Int J Cancer 88(5):733-736
19. Mandlekar S, Hebbar V, Christov K, Kong AN (2000) Pharmacodynamics of tamoxifen and its 4-hydroxy and N-desmethyl metabolites: Activation of caspases and induction of apoptosis in rat mammary tumors and in human breast cancer cell lines. Cancer Res 60(23):6601-6006
20. Mandlekar S, Yu R, Tan TH, Kong AN (2000) Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res 60(21):5995-6000
21. Ellis PA, Saccani-Jotti G, Clarke R, Johnston SR, Anderson E, Howell A, A'Hern R, Salter J, Detre S, Nicholson R et al (1997) Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int J Cancer 72(4):608-613
22. Hui AM, Zhang W, Chen W, Xi D, Purow B, Friedman GC, Fine HA (2004) Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. Cancer Res 64(24):9115-9123
23. Ward HW (1973) Anti-oestrogen therapy for breast cancer: A trial of tamoxifen at two dose levels. Br Med J 1(5844):13-14
24. Jordan VC, Dowse LJ (1976) Tamoxifen as an anti-tumour agent: Effect on oestrogen binding. J Endocrinol 68(02):297-303
25. Campanella M, Pinton P, Rizzuto R (2004) Mitochondrial Ca2+ homeostasis in health and disease. Biol Res 37(4):653-660
26. Mandlekar S, Kong AN (2001) Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6(6):469-477
27. Armstrong JS (2006) Mitochondria: A target for cancer therapy. Br J Pharmacol 147(3):239-248
28. Pinton P, Rizzuto R (2006) Bcl-2 and Ca2+ homeostasis in the endoplasmic reticulum. Cell Death Differ 13(8):1409-1418
29. Festjens N, Vanden Berghe T, Vandenabeele P (2006) Necrosis, a well-orchestrated form of cell demise: Signalling cascades, important mediators and concomitant immune response. Biochim Biophys Acta 1757(9-10):1371-1387
30. Pinton P, Ferrari D, Magalhaes P, Schulze-Osthoff K, Di Virgilio F, Pozzan T, Rizzuto R (2000) Reduced loading of intracellular Ca(2+) stores and downregulation of capacitative Ca(2+) influx in Bcl-2-overexpressing cells. J Cell Biol 148(5):857-862 857-862
31. Xu L, Kong D, Zhu L, Zhu W, Andrews DW, Kuo TH (2006) Suppression of IP3-mediated calcium release and apoptosis by Bcl-2 involves the participation of protein phosphatase 1. Mol Cell Biochem 295(1-2):153-165
32. Prakriya M, Feske S, Gwack Y, Srikanth S, Rao A, Hogan PG (2006) Orai1 is an essential pore subunit of the CRAC channel. Nature 443(7108):230-233
33. Chen R, Valencia I, Zhong F, McColl KS, Roderick HL, Bootman MD, Berridge MJ, Conway SJ, Holmes AB, Mignery GA et al (2004) Bcl-2 functionally interacts with inositol 1,4,5-trisphosphate receptors to regulate calcium release from the ER in response to inositol 1,4,5-trisphosphate. J Cell Biol 166(2):193-203
34. DeSouza N, Reiken S, Ondrias K, Yang YM, Matkovich S, Marks AR (2002) Protein kinase A and two phosphatases are components of the inositol 1,4,5-trisphosphate receptor macromolecular signaling complex. J Biol Chem 277(42):39397-39400
35. Zhang W, Couldwell WT, Song H, Takano T, Lin JH, Nedergaard M (2000) Tamoxifen-induced enhancement of calcium signaling in glioma and MCF-7 breast cancer cells. Cancer Res 60(19):5395-5400
36. Zhu W, Cowie A, Wasfy GW, Penn LZ, Leber B, Andrews DW (1996) Bcl-2 mutants with restricted subcellular location reveal spatially distinct pathways for apoptosis in different cell types. Embo J 15(16):4130-4141
37. Tsien RY, Rink TJ, Poenie M (1985) Measurement of cytosolic free Ca2+ in individual small cells using fluorescence microscopy with dual excitation wavelengths Cell Calcium 6(1-2):145-157
38. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65(1-2):55-63
39. Zhang SL, Yu Y, Roos J, Kozak JA, Deerinck TJ, Ellisman MH, Stauderman KA, Cahalan MD (2005) STIM1 is a Ca2+ sensor that activates CRAC channels, migrates from the Ca2+ store to the plasma membrane. Nature 437(7060):902-905
40. Sedova M, Klishin A, Huser J, Blatter LA (2000) Capacitative Ca2+ entry is graded with degree of intracellular Ca2+ store depletion in bovine vascular endothelial cells. J Physiol 523(Pt 3):549-559
41. Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R, Sainsbury R, Baum M (2006) Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 17(5):818-826
42. Tang P, Roldan G, Brasher PM, Fulton D, Roa W, Murtha A, Cairncross JG, Forsyth PA (2006) A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neurooncol 78(3):311-316
43. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I et al (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 20(16):3386-3395
44. Zagranichnaya TK, Wu X, Danos AM, Villereal ML (2005) Gene expression profiles in HEK-293 cells with low or high store-operated calcium entry: can regulatory as well as regulated genes be identified? Physiol Genomics 21(1):14-33 14-33
45. Tang TS, Tu H, Wang Z, Bezprozvanny I (2003) Modulation of type 1 inositol (1,4,5)-trisphosphate receptor function by protein kinase a and protein phosphatase 1alpha. J Neurosci 23(2):403-415
46. Dohadwala M, da Cruz e Silva EF, Hall FL, Williams RT, Carbonaro-Hall DA, Nairn AC, Greengard P, Berndt N (1994) Phosphorylation and inactivation of protein phosphatase 1 by cyclin-dependent kinases. Proc Natl Acad Sci USA 91(14):6408-6412
47. Zhang GJ, Kimijima I, Onda M, Kanno M, Sato H, Watanabe T, Tsuchiya A, Abe R, Takenoshita S (1999) Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels. Clin Cancer Res 5(10):2971-2977
48. Liu CW, Wang RH, Berndt N (2006) Protein phosphatase 1alpha activity prevents oncogenic transformation. Mol Carcinog 45(9):648-656
49. Garcia A, Cayla X, Guergnon J, Dessauge F, Hospital V, Rebollo MP, Fleischer A, Rebollo A (2003) Serine/threonine protein phosphatases PP1 and PP2A are key players in apoptosis. Biochimie 85(8):721-726